Satellos Bioscience Inc. Appoints Dr. Wildon Farwell as New Chief Medical Officer
- Satellos Bioscience Inc. appointed Dr. Wildon Farwell as Chief Medical Officer, effective July 16, 2025.
- Dr. Farwell will oversee the Phase 2 trial for SAT-3247, targeting muscle repair and regeneration.
- His experience enhances Satellos’ mission to develop innovative treatments for neuromuscular disorders beyond DMD.
Satellos Bioscience Inc. Appoints Dr. Wildon Farwell as Chief Medical Officer
Satellos Bioscience Inc., a clinical-stage biotech company dedicated to pioneering treatments for muscle diseases, recently announces the appointment of Dr. Wildon Farwell as its new Chief Medical Officer (CMO), effective July 16, 2025. Dr. Farwell transitions from Dyne Therapeutics, where he significantly contributed to the development of therapies for neuromuscular disorders, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). His extensive background in clinical development, particularly in advancing therapies through regulatory hurdles, positions him as a key player in Satellos’ mission to enhance treatment options for patients suffering from serious muscle-related conditions.
Dr. Farwell's leadership comes at a critical juncture for Satellos, as the company prepares to kick off a Phase 2 clinical trial for its lead candidate, SAT-3247. This innovative, orally administered small molecule aims to restore muscle repair and regeneration by targeting AAK1, a protein essential for muscle stem cell function. The successful advancement of SAT-3247 could mark a significant milestone not only for Satellos but for children with DMD, who currently face limited treatment options. Dr. Farwell’s role in overseeing the clinical development of SAT-3247 is expected to accelerate the company’s progress and deepen its commitment to developing transformative therapies in the neuromuscular disease arena.
In addition to his new role at Satellos, Dr. Farwell brings a wealth of experience from his tenure at Biogen, where he was instrumental in the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy. His comprehensive expertise spans clinical studies, regulatory submissions, and biomarker development, equipping Satellos with the knowledge and leadership necessary to navigate the complexities of clinical trials and bring innovative treatments to market. Dr. Farwell succeeds Dr. Jordan Dubow, who previously held the CMO position on a part-time basis and will continue to contribute as a consultant and chair of the Clinical Advisory Board.
In related news, Satellos aims to leverage its proprietary MyoReGenX™ discovery platform to explore treatment avenues for additional muscle diseases beyond DMD. This platform is designed to identify and develop therapies that can fundamentally alter the landscape of muscle disease treatment. The strategic appointment of Dr. Farwell highlights Satellos’ commitment to building a robust leadership team capable of driving innovation in the biotech sector and improving patient outcomes in neuromuscular disorders.
Overall, the appointment of Dr. Farwell marks a significant step forward for Satellos Bioscience Inc. in its quest to develop novel therapies for muscle diseases, reinforcing its strategic focus on clinical advancement and patient-centered solutions.